Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Oncology Unpaywall

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

The Lancet OncologyJan 1, 2014

Loading next page...
 
/lp/unpaywall/ibrutinib-as-initial-therapy-for-elderly-patients-with-chronic-0FVO0xE9t6

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Unpaywall
ISSN
1470-2045
DOI
10.1016/s1470-2045(13)70513-8
Publisher site
See Article on Publisher Site

Abstract

Journal

The Lancet OncologyUnpaywall

Published: Jan 1, 2014

There are no references for this article.